Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Cancer Cell International
Published in: Cancer Cell International 1/2022

Open Access 01-12-2022 | Breast Cancer | Primary research

ANLN and UBE2T are prognostic biomarkers associated with immune regulation in breast cancer: a bioinformatics analysis

Authors: Yu Xiao, Zhiqin Deng, Yongshen Li, Baoting Wei, Xiaoqiang Chen, Zhe Zhao, Yingjie Xiu, Meifang Hu, Murad Alahdal, Zhenhan Deng, Daping Wang, Jianquan Liu, Wencui Li

Published in: Cancer Cell International | Issue 1/2022

Login to get access

Abstract

Objectives

To screen and verify differential genes affecting the prognosis of breast cancer.

Methods

Breast cancer gene expression datasets were downloaded from the GEO database, and original data were analyzed in R. The TIMER database was used to analyze the relationship between ANLN and UBE2T and immune cell infiltration.

Results

Ten hub-key genes were identified, and survival analysis showed that UBE2T and ANLN were upregulated in breast cancer and their upregulation was associated with a poor prognosis. ANLN and UBE2T upregulation was associated with the prevalence of Th1 and Th2 cells, shifting the Th1/Th2 balance to Th2 in Basal and Luminal-B breast cancers, which indicates a poor prognosis (P < 0.05).

Conclusion

ANLN and UBE2T are potential biomarkers for predicting the prognosis of breast cancer.
Literature
1.
DeSantis C, Ma JM, Bryan L, Jemal A. Breast cancer statistics, 2013. CA Cancer J Clin. 2014;64(1):52–62.CrossRef
2.
3.
Tao ZQ, Shi AM, Lu CT, Song T, Zhang ZG, Zhao J. Breast cancer: epidemiology and etiology. Cell Biochem Biophys. 2015;72(2):333–8.CrossRef
4.
de Koning HJ, van Ineveld BM, de Haes JC, van Oortmarssen GJ, Klijn JG, van der Maas PJ. Advanced breast cancer and its prevention by screening. Br J Cancer. 1992;65(6):950–5.CrossRef
5.
Palesh O, Kamen C, Sharp S, Golden A, Neri E, Spiegel D, Koopman C. Physical activity and survival in women with advanced breast cancer. Cancer Nurs. 2018;41(4):E31–8.CrossRef
6.
van Maaren MC, Strobbe LJA, Smidt ML, Moossdorff M, Poortmans PMP, Siesling S. Ten-year conditional recurrence risks and overall and relative survival for breast cancer patients in the Netherlands: taking account of event-free years. Eur J Cancer. 2018;102:82–94.CrossRef
7.
Paik HJ, Lee SK, Ryu JM, Park S, Kim I, Bae SY, Yu J, Lee JE, Kim SW, Nam SJ. Conditional disease-free survival among patients with breast cancer. Medicine. 2017;96(1):e5746.CrossRef
8.
Janssen-Heijnen MLG, van Steenbergen LN, Voogd AC, Tjan-Heijnen VCG, Nijhuis PH, Poortmans PM, Coebergh JWW, van Spronsen DJ. Small but significant excess mortality compared with the general population for long-term survivors of breast cancer in the Netherlands. Ann Oncol. 2014;25(1):64–8.CrossRef
9.
van’t Veer LJ, Dai H, van de Vijver MJ, He YD, Hart AA, Mao M, Peterse HL, van der Kooy K, Marton MJ, Witteveen AT et al: Gene expression profiling predicts clinical outcome of breast cancer. Nature 2002, 415(6871):530–536.
10.
Paik S, Shak S, Tang G, Kim C, Baker J, Cronin M, Baehner FL, Walker MG, Watson D, Park T, et al. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med. 2004;351(27):2817–26.CrossRef
11.
Davis NM, Sokolosky M, Stadelman K, Abrams SL, Libra M, Candido S, Nicoletti F, Polesel J, Maestro R, D’Assoro A, et al. Deregulation of the EGFR/PI3K/PTEN/Akt/mTORC1 pathway in breast cancer: possibilities for therapeutic intervention. Oncotarget. 2014;5(13):4603–50.CrossRef
12.
Feng H, Gusev A, Pasaniuc B, Wu L, Long J, Abu-Full Z, Aittomäki K, Andrulis IL, Anton-Culver H, Antoniou AC, et al. Transcriptome-wide association study of breast cancer risk by estrogen-receptor status. Genet Epidemiol. 2020;44(5):442–68.CrossRef
13.
Pruneri G, Vingiani A, Denkert C. Tumor infiltrating lymphocytes in early breast cancer. Breast. 2018;37:207–14.CrossRef
14.
Li Y, Tao L, Cai W. Profiles of immune infiltration and prognostic immunoscore in lung adenocarcinoma. Biomed Res Int. 2020;2020:5858092.PubMedPubMedCentral
15.
Davis S, Meltzer PS. GEOquery: a bridge between the gene expression omnibus (GEO) and bioConductor. Bioinformatics (Oxford, England). 2007;23(14):1846–7.CrossRef
16.
Gu Z, Eils R, Schlesner M. Complex heatmaps reveal patterns and correlations in multidimensional genomic data. Bioinformatics (Oxford, England). 2016;32(18):2847–9.CrossRef
17.
Hänzelmann S, Castelo R, Guinney J. GSVA: gene set variation analysis for microarray and RNA-seq data. BMC Bioinformatics. 2013;14:7.CrossRef
18.
Xu J, Zheng H, Yuan S, Zhou B, Zhao W, Pan Y, Qi D. Overexpression of ANLN in lung adenocarcinoma is associated with metastasis. Thoracic Cancer. 2019;10(8):1702–9.CrossRef
19.
Xia L, Su X, Shen J, Meng Q, Yan J, Zhang C, Chen Y, Wang H, Xu M. ANLN functions as a key candidate gene in cervical cancer as determined by integrated bioinformatic analysis. CMAR. 2018;10:663–70.CrossRef
20.
Wang A, Dai H, Gong Y, Zhang C, Shu J, Luo Y, Jiang Y, Liu W, Bie P. ANLN-induced EZH2 upregulation promotes pancreatic cancer progression by mediating miR-218-5p/LASP1 signaling axis. J Exp Clin Cancer Res. 2019;38(1):347.CrossRef
21.
Sun J, Zhu Z, Li W, Shen M, Cao C, Sun Q, Guo Z, Liu L, Wu D. UBE2T-regulated H2AX monoubiquitination induces hepatocellular carcinoma radioresistance by facilitating CHK1 activation. J Exp Clin Cancer Res. 2020;39(1):222.CrossRef
22.
Liu LL, Zhu JM. UBE2T promotes proliferation via G2/M checkpoint in hepatocellular carcinoma. CMAR. 2019;11:8359–70.CrossRef
23.
Huang P, Guo Y, Zhao Z, Ning W, Wang H, Gu C, Zhang M, Qu Y, Zhang H, Song Y. UBE2T promotes glioblastoma invasion and migration via stabilizing GRP78 and regulating EMT. Aging. 2020;12(11):10275–89.CrossRef
24.
25.
Hao P, Kang B, Li Y, Hao W, Ma F. UBE2T promotes proliferation and regulates PI3K/Akt signaling in renal cell carcinoma. Mol Med Rep. 2019;20(2):1212–20.PubMedPubMedCentral
26.
Magnusson K, Gremel G, Rydén L, Pontén V, Uhlén M, Dimberg A, Jirström K, Pontén F. ANLN is a prognostic biomarker independent of Ki-67 and essential for cell cycle progression in primary breast cancer. BMC Cancer. 2016;16(1):904.CrossRef
27.
Wang Z, Chen J, Zhong MZ, Huang J, Hu YP, Feng DY, Zhou ZJ, Luo X, Liu ZQ, Jiang WZ, et al. Overexpression of ANLN contributed to poor prognosis of anthracycline-based chemotherapy in breast cancer patients. Cancer Chemother Pharmacol. 2017;79(3):535–43.CrossRef
28.
Zhou W, Wang Z, Shen N, Pi W, Jiang W, Huang J, Hu Y, Li X, Sun L. Knockdown of ANLN by lentivirus inhibits cell growth and migration in human breast cancer. Mol Cell Biochem. 2015;398(1–2):11–9.CrossRef
29.
Wang F, Xiang Z, Huang T, Zhang M, Zhou WB. ANLN directly interacts with RhoA to promote doxorubicin resistance in breast cancer cells. CMAR. 2020;12:9725–34.CrossRef
30.
31.
Ali HR, Chlon L, Pharoah PD, Markowetz F. Patterns of immune infiltration in breast cancer and their clinical implications: a gene-expression-based retrospective study. PLoS Med. 2016;13(12): e1002194.CrossRef
32.
Zhao X, Liu J, Ge S, Chen C, Li S, Wu X, Feng X, Wang Y, Cai D. Saikosaponin A inhibits breast cancer by regulating Th1/Th2 balance. Front Pharmacol. 2019;10:624.CrossRef
33.
Zhang W, Pan Y, Gou P, Zhou C, Ma L, Liu Q, Du Y, Yang J, Wang Q. Effect of xanthohumol on Th1/Th2 balance in a breast cancer mouse model. Oncol Rep. 2018;39(1):280–8.PubMed
34.
Mulligan AM, Pinnaduwage D, Tchatchou S, Bull SB, Andrulis IL. Validation of intratumoral T-bet+ lymphoid cells as predictors of disease-free survival in breast cancer. Cancer Immunol Res. 2016;4(1):41–8.CrossRef
35.
Thorsson V, Gibbs DL, Brown SD, Wolf D, Bortone DS, Ou Yang TH, Porta-Pardo E, Gao GF, Plaisier CL, Eddy JA, et al. The immune landscape of cancer. Immunity. 2018;48(4):812-830.e814.CrossRef
36.
Colak D, Nofal A, Albakheet A, Nirmal M, Jeprel H, Eldali A, Al-Tweigeri T, Tulbah A, Ajarim D, Malik OA, et al. Age-specific gene expression signatures for breast tumors and cross-species conserved potential cancer progression markers in young women. PLoS ONE. 2013;8(5): e63204.CrossRef
37.
Perez-Peña J, Corrales-Sánchez V, Amir E, Pandiella A, Ocana A. Ubiquitin-conjugating enzyme E2T (UBE2T) and denticleless protein homolog (DTL) are linked to poor outcome in breast and lung cancers. Sci Rep. 2017;7(1):17530.CrossRef
38.
Gao R, Bai S, Henderson YC, Lin Y, Schalck A, Yan Y, Kumar T, Hu M, Sei E, Davis A, et al. Delineating copy number and clonal substructure in human tumors from single-cell transcriptomes. Nat Biotechnol. 2021;39(5):599–608.CrossRef
39.
Maryam A, Chin YR. ANLN enhances triple-negative breast cancer stemness through TWIST1 and BMP2 and promotes its spheroid growth. Front Mol Biosci. 2021;8: 700973.CrossRef
Metadata
Title
ANLN and UBE2T are prognostic biomarkers associated with immune regulation in breast cancer: a bioinformatics analysis
Authors
Yu Xiao
Zhiqin Deng
Yongshen Li
Baoting Wei
Xiaoqiang Chen
Zhe Zhao
Yingjie Xiu
Meifang Hu
Murad Alahdal
Zhenhan Deng
Daping Wang
Jianquan Liu
Wencui Li
Publication date
01-12-2022
Publisher
BioMed Central
Published in
Cancer Cell International / Issue 1/2022
Electronic ISSN: 1475-2867
DOI
https://doi.org/10.1186/s12935-022-02611-0

Other articles of this Issue 1/2022

Cancer Cell International 1/2022 Go to the issue

Research

Exploring the relationship between autophagy and Gefitinib resistance in NSCLC by silencing PDLIM5 using ultrasound-targeted microbubble destruction technology

Primary research

MiR-937-3p promotes metastasis and angiogenesis and is activated by MYC in lung adenocarcinoma

Primary research

ZBTB7A, a miR-144-3p targeted gene, accelerates bladder cancer progression via downregulating HIC1 expression

Primary Research

Molecular mechanism by which CDCP1 promotes proneural-mesenchymal transformation in primary glioblastoma

Research

N6-methyladenosine methylation modification patterns reveal immune profiling in pancreatic adenocarcinoma

Primary research

MicroRNA-146a promotes proliferation, migration, and invasion of HepG2 via regulating FLAP
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits